{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T07:08:44Z","timestamp":1788764924838,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PC: GR-2021-12374462"],"award-info":[{"award-number":["PC: GR-2021-12374462"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.prp.2026.156642","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:25:01Z","timestamp":1786033501000},"page":"156642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integrated morphologic, immunophenotypic, and molecular profiling of advanced upper tract urothelial carcinoma across tumor compartments supports biopsy-based testing"],"prefix":"10.1016","volume":"287","author":[{"given":"Filippo Maria","family":"Martelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7069-7980","authenticated-orcid":false,"given":"Giuseppe Nicol\u00f2","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Stefanizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vicentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-8991","authenticated-orcid":false,"given":"Lisa","family":"Marcolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7881-8767","authenticated-orcid":false,"given":"Stefano","family":"Marletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5313-0971","authenticated-orcid":false,"given":"Cinzia","family":"Giacometti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Bertoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bertoldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Salvagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cali\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7761-7274","authenticated-orcid":false,"given":"Guido","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update","volume":"84","author":"Roupret","year":"2023","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.prp.2026.156642_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-010-0594-7","article-title":"Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma","volume":"29","author":"Shariat","year":"2011","journal-title":"World J. Urol."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00345-012-0877-2","article-title":"Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma","volume":"31","author":"Cosentino","year":"2013","journal-title":"World J. Urol."},{"issue":"4","key":"10.1016\/j.prp.2026.156642_bib4","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.21037\/tau.2019.12.21","article-title":"Risk stratification for upper tract urinary carcinoma","volume":"9","author":"Benamran","year":"2020","journal-title":"Transl. Androl. Urol."},{"issue":"4","key":"10.1016\/j.prp.2026.156642_bib5","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2214\/AJR.14.13167","article-title":"T categorization of urothelial carcinomas of the ureter with CT: preliminary study of new diagnostic criteria proposed for differentiating T2 or lower from T3 or higher","volume":"204","author":"Honda","year":"2015","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.prp.2026.156642_bib7","first-page":"261","article-title":"Upper urinary tract disease: what we know today and unmet needs","volume":"4","author":"Mathieu","year":"2015","journal-title":"Transl. Androl. Urol."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.2011.10288.x","article-title":"Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma","volume":"109","author":"Favaretto","year":"2012","journal-title":"BJU Int."},{"issue":"8","key":"10.1016\/j.prp.2026.156642_bib9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.urolonc.2012.05.010","article-title":"Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma","volume":"31","author":"Rojas","year":"2013","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156642_bib10","first-page":"242","article-title":"Diagnosis and kidney-sparing treatments for upper tract urothelial carcinoma: state of the art","volume":"70","author":"Territo","year":"2018","journal-title":"Minerva Urol. Nefrol."},{"issue":"5","key":"10.1016\/j.prp.2026.156642_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur. Urol."},{"issue":"23","key":"10.1016\/j.prp.2026.156642_bib12","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.3390\/cancers15235558","article-title":"Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice","volume":"15","author":"Lefort","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.prp.2026.156642_bib13","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.prp.2026.156642_bib14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2026.156642_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2009.08.115","article-title":"Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer","volume":"183","author":"Shariat","year":"2010","journal-title":"J. Urol."},{"issue":"10031","key":"10.1016\/j.prp.2026.156642_bib17","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.prp.2026.156642_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.prp.2026.156642_bib19","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdw170","article-title":"Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment","volume":"27","author":"Pouessel","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156642_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.euf.2018.01.005","article-title":"Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens","volume":"5","author":"Bagrodia","year":"2019","journal-title":"Eur. Urol. Focus."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s42269-024-01237-8","article-title":"Immunohistochemical expression of GATA3, CK5\/6 and CK20 in molecular subtypes of bladder carcinoma: correlation with clinicopathological features","volume":"48","author":"Yassen","year":"2024","journal-title":"Bull. Natl. Res. Cent."},{"issue":"2","key":"10.1016\/j.prp.2026.156642_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/his.13225","article-title":"p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant","volume":"71","author":"Hodgson","year":"2017","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.prp.2026.156642_bib23","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic Characterization of Upper Tract Urothelial Carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.prp.2026.156642_bib24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/ijms22020628","article-title":"Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.prp.2026.156642_bib25","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","article-title":"Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites","volume":"25","author":"Nassar","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2026.156642_bib26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.euo.2020.04.005","article-title":"Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study","volume":"4","author":"Necchi","year":"2021","journal-title":"Eur. Urol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib27","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.prp.2026.156642_bib28","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur. Urol. Focus."},{"issue":"6","key":"10.1016\/j.prp.2026.156642_bib29","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.prp.2026.156642_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048993","article-title":"A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer","volume":"7","author":"Neuzillet","year":"2012","journal-title":"PLoS. One"},{"issue":"2","key":"10.1016\/j.prp.2026.156642_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","article-title":"Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants","volume":"75","author":"Warrick","year":"2019","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.prp.2026.156642_bib33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4111\/icu.20200425","article-title":"Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer","volume":"62","author":"Razzaghdoust","year":"2021","journal-title":"Investig. Clin. Urol."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1389202923666220204155828","article-title":"Molecular Characterization of Upper Tract Urothelial Carcinoma for Precision Therapeutics and Non-invasive Diagnostics","volume":"23","author":"Sugawara","year":"2022","journal-title":"Curr. Genom."},{"issue":"9","key":"10.1016\/j.prp.2026.156642_bib35","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/biomedicines12092154","article-title":"Biomarker Profiling of Upper Tract Urothelial Carcinoma Only and with Synchronous or Metachronous Bladder Cancer","volume":"12","author":"Meireles","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sjodahl","year":"2017","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.prp.2026.156642_bib37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00428-019-02593-x","article-title":"Predicting outcomes in non-muscle invasive (Ta\/T1) bladder cancer: the role of molecular grade based on luminal\/basal phenotype","volume":"475","author":"Rebola","year":"2019","journal-title":"Virchows Arch."},{"issue":"3","key":"10.1016\/j.prp.2026.156642_bib38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00428-019-02618-5","article-title":"Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder","volume":"475","author":"Rodriguez Pena","year":"2019","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2026.156642_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.humpath.2020.01.004","article-title":"The applicability and utility of immunohistochemical biomarkers in bladder pathology","volume":"98","author":"Akgul","year":"2020","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2026.156642_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.prp.2026.156642_bib41","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2021\/e2587","article-title":"Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes","volume":"76","author":"Ravanini","year":"2021","journal-title":"Clin. (Sao Paulo)"},{"issue":"11","key":"10.1016\/j.prp.2026.156642_bib42","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/jclinpath-2021-207573","article-title":"Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression","volume":"75","author":"Olkhov-Mitsel","year":"2022","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.prp.2026.156642_bib43","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.2892","article-title":"Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma","volume":"224","author":"Al-Ahmadie","year":"2011","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J. Pathol."},{"issue":"21","key":"10.1016\/j.prp.2026.156642_bib45","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156642_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.prp.2026.156642_bib47","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma","volume":"64","author":"van Rhijn","year":"2004","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2026.156642_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00143","article-title":"Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome","volume":"2018","author":"Donahue","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156642_bib49","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"issue":"7492","key":"10.1016\/j.prp.2026.156642_bib50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.prp.2026.156642_bib51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","article-title":"Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes","volume":"17","author":"Meeks","year":"2020","journal-title":"Nat. Rev. Urol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:33:46Z","timestamp":1788762826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":51,"alternative-id":["S0344033826002955"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156642","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated morphologic, immunophenotypic, and molecular profiling of advanced upper tract urothelial carcinoma across tumor compartments supports biopsy-based testing","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"156642"}}